James M. Oliphant
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: Agricultural Research Service (2008); United States Food and Drug Administration (2024–2025); United States Department of Agriculture (2008); National Clonal Germplasm Repository (2008)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
James M. Oliphant's research focuses on developing and validating methods for toxicity screening and drug development, particularly concerning drug-induced liver injury. He has investigated the use of lab-on-a-chip platforms for measuring biomarkers associated with liver damage and has explored the application of cardiac NAMs (New Approach Methodologies) for toxicity assessment. His work also extends to metabolomics and lipidomics, with recent efforts identifying disease severity biomarkers in COVID-19 patient plasma. Oliphant's scholarship metrics include an h-index of 5, with 9 total publications and 83 citations. He has collaborated with researchers such as Tucker A. Patterson, Laura K. Schnackenberg, Qiang Shi, and Katy S Papineau, all from the National Center for Toxicological Research, sharing one publication with each.
Metrics
- h-index: 5
- Publications: 9
- Citations: 83
Selected Publications
-
Evaluation of BMI and fat distribution as potential risk factors for infection and wound healing complications in total hip arthroplasty (2026)
-
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)
-
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025)
-
Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers (2024)
Collaboration Network
Top Collaborators
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
Similar Researchers
Based on overlapping research topics